Identification of drug/protein adducts in biological samples treated with antitumoral Pt-containing drugs

Pt-containing drugs have been used for decades in antitumoral therapies and their action mechanisms are partially described in the literature. However, the complete antitumoral mechanisms as well as important secondary effects and resistance behaviours are not fully explained. For this reason, the protein fraction of different tissues can provide important information in the study of such side effects. However, until the moment there is a lack of analytical methodologies involving platinated species in real samples. The development of analytical tools that allow studying which proteins interact with the Pt-drugs in real samples, will help to understand these side effects. Thus, new administration protocols of the current drugs as well as the design of more effective and less toxic drugs can be tackled with the obtained information.